about
Two-stage designs for cross-over bioequivalence trials.A weighted combined effect measure for the analysis of a composite time-to-first-event endpoint with components of different clinical relevance.Time-to-first-event versus recurrent-event analysis: points to consider for selecting a meaningful analysis strategy in clinical trials with composite endpoints.What makes a biostatistician?Comprehensive survey among statistical members of medical ethics committees in Germany on their personal impression of completeness and correctness of biostatistical aspects of submitted study protocolsA variational approach to optimal two-stage designsA new conditional performance score for the evaluation of adaptive group sequential designs with sample size recalculation
P50
Q41158950-D39A2067-3771-404A-BD5C-D5A1B8DF3908Q48180336-A80970D5-3E7B-4A66-81C6-518C1E109FB4Q49909944-EF729336-4463-4B71-90E3-3A48CECE25BCQ57183112-965B7BFB-7E6F-4ED9-9DB8-31E25E587434Q89555250-C8B0CF1C-8152-471B-ABB0-EF90BF3A984FQ91539636-2AAC40C1-60D9-4AA3-AA39-AEC9782BC1C3Q91584979-1B9128A5-AAFA-49F4-A8CC-2FB16CB4CFD2
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Geraldine Rauch
@ast
Geraldine Rauch
@en
Geraldine Rauch
@es
Geraldine Rauch
@nl
type
label
Geraldine Rauch
@ast
Geraldine Rauch
@en
Geraldine Rauch
@es
Geraldine Rauch
@nl
prefLabel
Geraldine Rauch
@ast
Geraldine Rauch
@en
Geraldine Rauch
@es
Geraldine Rauch
@nl
P214
P244
P106
P214
P244
n2018189291
P31
P3762
P496
0000-0002-2451-1660
P734
P7859
lccn-n2018189291